Millions of people suffer from sleep apnea every single night. We will not rest until they sleep peacefully.

We are Invicta Medical™

Sleep apnea is a chronic condition that impacts nearly 30 million adults in the U.S., with 80% undiagnosed.

When untreated, sleep apnea is linked to serious and costly conditions, including drug-resistant hypertension, obesity, congestive heart failure, type-2 diabetes, atrial fibrillation and more.

Untreated sleep apnea costs the U.S. approximately $150 billion annually, due to the healthcare costs associated with these untreated conditions, as well as loss of productivity, workplace accidents and motor vehicle accidents.

Current solutions are not working. Continuous positive airway pressure (CPAP) therapy accounts for 85% of diagnosed sleep apnea patients, yet nearly half don’t comply with the therapy. The devices are cumbersome, loud, uncomfortable and overall intrusive.

Patients need a better option.

Invicta Medical is changing the sleep apnea treatment paradigm from high-cost, complex machines, to smart, comfortable and cost-effective solutions.

Invicta Medical is a clinical-stage medical technology company developing a first-of-its-kind treatment for sleep apnea.

Invicta’s intelligent neurostimulation wearable is designed to address the shortcomings of existing therapies, which are expensive, intrusive and yield low patient compliance rates.

Invicta has raised $28.6 million in funding since 2013 and is backed by international investors and Tier 1 investment firms.

Invicta’s Board of Directors have extensive operational and financial experience in industries ranging from medical technologies and life sciences to semiconductors to robotics, while its Scientific Advisors hail from top universities and medical institutions, including Stanford University, John Hopkins University, Karolinska Institute and the University of Pittsburgh Medical Center.

Eclipse Logo Great Point Logo
Invicta Medical Logo

We Keep People Breathing

EXECUTIVE TEAMBOARD OF DIRECTORS

Sign up for news about our latest developments

Sign Up For News